Meta-analyses show that semaglutide increases the likelihood of discontinuing treatment (relative risk 1.67, 95% CI 1.27-2.21), primarily due to gastrointestinal adverse events like nausea, vomiting, and diarrhea
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients
Bacteriostatic water, mannitol (a common filler in lyophilized peptides), and the peptide itself should meet United States Pharmacopeia standards
Cell Cycle 17 , 16021613
95% CI, 0.72-0.98) and rectal cancer (HR = 0.72
Inactive: Aqua (Water), Caprylic/Capric Triglyceride, Corn Starch Modified, Cetearyl Olivate, Diethylhexyl 2,6-Naphthalate, C12-15 Alkyl Benzoate, Sorbitan Olivate, Gluconolactone, Cyclopentasiloxane, Glycerin, Squalane, Phenoxyethanol, Sodium Benzoate, Caprylyl Glycol, Xanthan Gum, Aminomethyl Propanol, Carbomer, Tocopheryl Acetate (D-alpha), Sodium Hyaluronate (L), Trisodium Ethylenediamine Disuccinate, Phenethyl Alcohol, Potassium Sorbate, Hamamelis Virginiana (Witch Hazel) Water, Citric Acid, Alcohol, Sodium Hydroxide